Cutler Group LP Myovant Sciences Ltd. Call Options Transaction History

Cutler Group LP

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2022 Feb 07, 2023	BUY	$24.03 - $27.02 $288,360 - $324,240	12,000 Added 105.26%	23,400 $27,000
Q3 2022 Oct 25, 2022	SELL	$11.6 - $20.44 $11,600 - $20,440	-1,000 Reduced 8.06%	11,400 $14,000
Q2 2022 Aug 04, 2022	BUY	$7.78 - $14.69 $3,112 - $5,876	400 Added 3.33%	12,400 $7,000
Q1 2022 Apr 14, 2022	BUY	$11.38 - $16.4 $114,938 - $165,640	10,100 Added 531.58%	12,000 $12,000
Q1 2021 Apr 26, 2021	SELL	$20.46 - $25.18 $18,414 - $22,662	-900 Reduced 32.14%	1,900 $0
Q4 2020 Jan 21, 2021	SELL	$13.8 - $27.62 $102,120 - $204,388	-7,400 Reduced 72.55%	2,800 $19,000
Q3 2020 Oct 27, 2020	BUY	$14.05 - $22.6 $28,100 - $45,200	2,000 Added 24.39%	10,200 $1,000
Q2 2020 Jul 22, 2020	SELL	$7.34 - $20.84 $2,202 - $6,252	-300 Reduced 3.53%	8,200 $36,000
Q1 2020 May 07, 2020	SELL	$6.55 - $14.76 $2,620 - $5,904	-400 Reduced 4.49%	8,500 $2,000
Q4 2019 Feb 06, 2020	BUY	$4.2 - $19.21 $37,380 - $170,969	8,900 New	8,900 $28,000

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.